Generic Besivance Availability
Last updated on Jan 8, 2025.
Besivance is a brand name of besifloxacin ophthalmic, approved by the FDA in the following formulation(s):
BESIVANCE (besifloxacin hydrochloride - suspension/drops;ophthalmic)
-
Manufacturer: BAUSCH AND LOMB
Approval date: May 28, 2009
Strength(s): EQ 0.6% BASE [RLD]
Has a generic version of Besivance been approved?
No. There is currently no therapeutically equivalent version of Besivance available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Besivance. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Besifloxacin ophthalmic composition for the treatment or control of infection
Patent 8,415,342
Issued: April 9, 2013
Inventor(s): Tyle Praveen & Gupta Pramod Kumar & Norton Susan E. & Brunner Lynne & Blondeau Joseph
Assignee(s): Bausch & Lomb IncorporatedA composition comprises besifloxacin in an amount effective for treating or controlling an infection caused by an antibiotic-resistant bacterium. Such a composition can be administered to a subject for the treatment or control of bacterial conjunctivitis caused bay an antibiotic-resistant bacterium.
Patent expiration dates:
- November 7, 2030✓
- November 7, 2030
-
Fluoroquinolone carboxylic acid molecular crystals
Patent 8,481,526
Issued: July 9, 2013
Inventor(s): King & Jr. Harry M.
Assignee(s): Bausch & Lomb IncorporatedDisclosed herein is a molecular crystal form of the compound (R)-(+)-7-(3-amino-2,3,4,5,6,7-hexahydro-1H-azepin-1-yl)-1-cyclopropyl-8-chloro-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid. The molecular crystal is characterized by at least one of: (a) an X-ray powder diffraction (“XRPD”) spectrum that comprises peaks at 2θ angles of 10.6, 15, 19.7, 21.1, and 22°±0.2°; (b) a DSC melting peak at 288° C.; (c) a C NMR spectrum having peaks at 23.3, 27.7, 41.1, 54.5, 116.6, and 153.5 ppm; and (d) pKa values of 5.65 and 9.91. The compound belongs to the class of fluoroquinolones and is useful as an antibacterial agent.
Patent expiration dates:
- January 9, 2031✓
- January 9, 2031
-
Fluoroquinolone carboxylic acid molecular crystals
Patent 8,604,020
Issued: December 10, 2013
Inventor(s): King & Jr. Harry M.
Assignee(s): Bausch & Lomb IncorporatedDisclosed herein is a molecular crystal form of (R)-(+)-7-(3-amino-2,3,4,5,6,7-hexahydro-1H-azepin-1-yl)-1-cyclopropyl-8-chloro-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid. The molecular crystal is characterized by at least one of: (a) an X-ray powder diffraction (“XRPD”) spectrum that comprises peaks at 2θ angles of 10.6, 15, 19.7, 21.1, and 22°±0.2°; (b) a DSC melting peak at 288° C.; (c) a C NMR spectrum having peaks at 23.3, 27.7, 41.1, 54.5, 116.6, and 153.5 ppm; and (d) pKa values of 5.65 and 9.91. The compound belongs to the class of fluoroquinolones and is useful as an antibacterial agent.
Patent expiration dates:
- March 12, 2030✓
- March 12, 2030
-
Compositions and methods for treating, reducing, ameliorating, or preventing infections caused by antibacterial drug-resistant bacteria
Patent 8,937,062
Issued: January 20, 2015
Inventor(s): Tyle Praveen & Gupta Pramod Kumar & Norton Susan E. & Brunner Lynne & Blondeau Joseph
Assignee(s): Bausch & Lomb IncorporatedCompositions comprise a fluoroquinolone having Formulae I-VIII for treating, reducing, ameliorating, or preventing infections caused by some bacteria that are resistant to an antibacterial drug. Methods for treating, reducing, ameliorating, or preventing such infections use such compositions.
Patent expiration dates:
- November 13, 2029✓
- November 13, 2029
More about Besivance (besifloxacin ophthalmic)
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: ophthalmic anti-infectives
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.